HNRNPC与m6A RNA甲基化调控T细胞白血病致癌转录与代谢
该研究首次揭示T细胞急性淋巴细胞白血病(T-ALL)患者存在广泛的m6A改变,发现m6A调控MYC和胆固醇生物合成通路,T-ALL高度依赖m6A阅读蛋白HNRNPC,且FTO在T-ALL细胞中显著升高,靶向FTO在临床前模型中显示治疗潜力并与临床相关药物协同。
要点
- T-ALL患者存在广泛的m6A修饰改变,m6A调控MYC和胆固醇生物合成通路。
- T-ALL高度依赖m6A阅读蛋白HNRNPC,其转录沉默可损害致癌通路并显著抑制白血病细胞生长。
- FTO在T-ALL细胞中较正常细胞及其他类型白血病显著升高,靶向FTO在临床前模型中与临床相关药物协同。
核心结论
- RNA甲基化在协调癌细胞致癌基因表达和代谢中起整体性作用,并为T细胞白血病治疗提供有前景的新途径。
研究设计与样本
- 研究对T-ALL患者的m6A改变进行了分析,并开展相关机制与临床前模型研究。
主要发现
- T-ALL患者存在广泛的m6A改变,m6A调控致癌MYC和胆固醇生物合成通路。
- HNRNPC受MYC转录调控,是m6A修饰转录本的关键调节因子,其转录沉默深刻损害致癌通路并显著削弱白血病细胞生长。
- FTO水平在T-ALL细胞中较正常细胞及其他类型白血病细胞显著升高。
- 靶向FTO在临床前疾病模型中显示治疗潜力,并与临床相关治疗药物协同。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RNA homeostasis is dysregulated in cancer and affects disease progression and therapy resistance. N6-methyladenosine (m6A), the most abundant epitranscriptomic modification in eukaryotic messenger RNA, plays a pivotal role in RNA biology, affecting transcript stability, translation, and splicing. Our study uncovers the extensive m6A changes in patients with T-cell acute lymphoblastic leukemia (T-ALL), to our knowledge, for the first time. It reveals m6A's regulatory role in the oncogenic MYC and cholesterol biosynthesis pathways. In addition, we discovered that T-ALL is highly dependent on the m6A reader heterogeneous nuclear ribonucleoprotein C (HNRNPC). HNRNPC is transcriptionally controlled by MYC and is an essential regulator of m6A-modified transcripts. Consequently, transcriptional silencing of HNRNPC profoundly impairs oncogenic pathways and critically diminishes leukemia cell growth. In addition, the levels of the m6A demethylase fat mass and obesity-associated protein (FTO) are significantly elevated in T-ALL cells compared with normal cells, and to other types of leukemia. Targeting FTO shows therapeutic potential in preclinical disease models and synergizes with clinically relevant therapeutics. Our findings underscore the integral role of RNA methylation in orchestrating cancer cell oncogene expression and metabolism and highlight promising novel therapeutic avenues for the treatment of T-cell leukemia.
引用
- De Kesel J, Fijalkowski I, Pieters T, et al. HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia. Blood. 2025. PMID: 40435411. doi:10.1182/blood.2024026848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。